On this page
What each program costs in Connecticut
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does Connecticut Medicaid (HUSKY Health) cover GLP-1s for weight loss?
Not covered for weight loss
A 2026 Connecticut Department of Social Services decision says weight-loss drug coverage is limited to orlistat and phentermine and that Zepbound is not approved for weight loss, so HUSKY Health does not cover Wegovy or Zepbound for weight loss alone. Read from state documents Nov 6, 2026.
What Connecticut Medicaid (HUSKY Health)'s documents say about each drug for weight loss. Read Nov 6, 2026. Connecticut Department of Social Services.
WegovyNo
Listed uses are preventing major heart events in patients with obesity and certain heart conditions, and MASH.
“With respect to FDA approved weight loss medications, the only medications for which coverage is afforded are orlistat and phentermine.”
Connecticut Department of Social Services, hearing decision citing state plan amendment 25-0014 · No effective date on the document · read Nov 6, 2026
“For prevention of MACE (major adverse cardiac event) in patients with obesity and history of certain cardiovascular conditions”
Connecticut Department of Social Services, presentation to the Medical Assistance Program Oversight Council · No effective date on the document · read Nov 6, 2026
ZepboundNo
Prior authorization for obstructive sleep apnea in adults 18 and older, with airway pressure treatment and lifestyle program rules.
“under the HUSKY Health Plan Zepbound is not approved for weight loss with a diagnosis of obesity.”
Connecticut Department of Social Services, hearing decision · No effective date on the document · read Nov 6, 2026
“With respect to FDA approved weight loss medications, the only medications for which coverage is afforded are orlistat and phentermine.”
Connecticut Department of Social Services, hearing decision citing state plan amendment 25-0014 · No effective date on the document · read Nov 6, 2026
OzempicNo
The department lists Ozempic for type 2 diabetes.
“For treatment of Type 2 diabetes (Ozempic, Trulicity, Victoza)”
Connecticut Department of Social Services, presentation to the Medical Assistance Program Oversight Council · No effective date on the document · read Nov 6, 2026
“the medication approved for weight loss is limited to orlistat and phentermine.”
Connecticut Department of Social Services, hearing decision · No effective date on the document · read Nov 6, 2026
MounjaroNot confirmed
No state document read names Mounjaro. The department's December 2025 GLP-1 list does not include it, and ctdssmap.com, which hosts the bulletins, could not be reached.
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Connecticut Department of Social Services documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
- Jul 1, 2025 · Policy changeHUSKY Health began paying for new Zepbound prescriptions for obstructive sleep apnea.
“Effective July 1, 2025, the Department will reimburse for new prescriptions for Zepbound through the pharmacy benefit”
Connecticut Department of Social Services, hearing decision quoting Provider Bulletin 2025-32 · Effective Jul 1, 2025 · read Nov 6, 2026
- Jun 1, 2025 · Policy changeCMS approved a state plan amendment updating Connecticut's excluded drug list, with weight-loss coverage limited to orlistat and phentermine.
“approved by Centers for Medicare and Medicaid on June 1, 2025 provides updates to the State's excluded drug listing.”
Connecticut Department of Social Services, hearing decision · No effective date on the document · read Nov 6, 2026
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
5,475 prescriptions
Ozempic and Mounjaro, 2025
152,180 prescriptions
Neighbours covering weight loss
0 of 3
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Connecticut Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Connecticut Medicaid as "not covered" for GLP-1s for obesity under fee-for-service. Connecticut Medicaid covers one or more older weight-loss drugs, but no GLP-1.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Connecticut Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Connecticut Medicaid pay for?
174,430 GLP-1 prescriptions in 2025, 16th of the 50 states and DC, with $199.9 million reimbursed before rebates. Counting the share other payers covered, $202.7 million.
Prescriptions, 2025
174,430
16th of 51
Medicaid paid
$199.9M
16th of 51, before rebates
Per prescription
$1,146
$1,051 nationally
Weight-loss brands
3.1%
27th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Connecticut is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 3.1% of Connecticut Medicaid's GLP-1 prescriptions in 2025 (5,475). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Ozempic was Connecticut Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Ozempic | 101,853 | 58% | $113.7 million | $1,116 |
| Mounjaro | 50,327 | 29% | $59.7 million | $1,186 |
| Trulicity | 13,087 | 7.5% | $15.6 million | $1,189 |
| Zepboundapproved for weight management | 3,350 | 1.9% | $3.7 million | $1,112 |
| Rybelsus | 3,083 | 1.8% | $4.4 million | $1,426 |
| Wegovyapproved for weight management | 2,125 | 1.2% | $2.5 million | $1,164 |
| Victoza | 356 | 0.2% | $272,420 | $765 |
| Liraglutide (generic) | 249 | 0.1% | $132,969 | $534 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in Connecticut?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 2 in Connecticut. The register does not say which, if any, supplies a program on this page.
- Brookfield Medical/Surgical Supply, Inc., Brookfield. Registered since Jan 12, 2015; last FDA inspection Jul 10, 2026.
- SCA Pharmaceuticals, Windsor. Registered since Aug 3, 2017; last FDA inspection Mar 13, 2026.
On Medicare in Connecticut?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Connecticut and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 3 states next to Connecticut covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than Connecticut's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Connecticut | Not covered | 19 | $39/mo |
| Massachusetts | Not covered | 18 | $39/moWellmedr |
| New York | Not covered | 19 | $39/moWellmedr |
| Rhode Island | Not confirmed | 19 | $39/moWellmedr |






















